Skip to Content

ESMO24: New Standard of Care – Immunotherapy in High-Risk Locally Advanced Cervical Cancer

At ESMO 2024, the 3-year results from the KEYNOTE-A18 study were presented, showing a clinically meaningful benefit of adding immunotherapy to the treatment regimen.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top